AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17146383 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g intravenous acetaminophen (Perfalgan)
Number of subjects: 74
Study 17146383 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (placebo)
Number of subjects: 74
Study 12681003 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 50 mg/day
Number of subjects: 5
Study 12681003 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 100 mg/day
Number of subjects: 5
Study 12681003 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 200 mg/day (nonobese)
Number of subjects: 5
Study 12681003 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 200 mg/day (obese)
Number of subjects: 5
Study 12681003 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 600 mg/day
Number of subjects: 5
Study 10741623 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg three times a day
Number of subjects: 9
Study 10741623 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg once a day
Number of subjects: 9
Study 10741623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9373813 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (200 mg = 0.855 mM)
Number of subjects: 20
Study 9373813 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine (200 mg = 0.909 mM)
Number of subjects: 20
Study 9373813 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 20
Study 9373813 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine
Number of subjects: 20
Study 8245589 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive intrauterine therapy including tocolytic agents (ritodrine and/or magnesium sulfate) and prophylactic antibiotics (AB‐PC 2g/day)
Number of subjects: 75
Study 8245589 — intervention group
Group type: COMPARATOR
Intervention: Conservative management with bed rest only
Number of subjects: 75
Study 8245589 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive intrauterine therapy including tocolytic agents and prophylactic antibiotics
Number of subjects: 75
Study 3754202 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-hydrolyzed milk
Number of subjects: 20
Study 3754202 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhydrolyzed milk
Number of subjects: 20
Study 3754202 — intervention group
Group type: COMPARATOR
Intervention: Lactose-hydrolyzed milk and unhydrolyzed milk
Number of subjects: 20
Study 31987569 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender oil massage in addition to routine care
Number of subjects: 90
Study 31987569 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin oil massage in addition to routine care
Number of subjects: 90
Study 31987569 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care only)
Number of subjects: 90
Study 29656304 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-collagen implant (GCI) applied in the pelvic cavity after total mesorectal excision (TME)
Number of subjects: 176
Study 29656304 — intervention group
Group type: COMPARATOR
Intervention: Control group without GCI
Number of subjects: 176
Study 29656304 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-collagen implant (GCI)
Number of subjects: 176
Study 27355231 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual methylcobalamin (1mg/day for 3 months)
Number of subjects: 34
Study 27355231 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular hydroxocobalamin injection (1mg)
Number of subjects: 34
Study 24989822 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet-based physical activity intervention
Number of subjects: 30
Study 22846707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Number of subjects: 42
Study 22846707 — intervention group
Group type: COMPARATOR
Intervention: Symptom diary control
Number of subjects: 42
Study 19776646 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat beta-methasone (12 mg)
Number of subjects: 22
Study 19776646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 19776646 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat beta-methasone
Number of subjects: 22
Study 18272913 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line carboplatin/taxane chemotherapy, with carboplatin dose determined by measured glomerular filtration rate (GFR) and taxane dose not capped.
Number of subjects: 1067
Study 18272913 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line carboplatin/taxane chemotherapy
Number of subjects: 1067
Study 15720089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional Candida antigen
Number of subjects: 17
Study 15720089 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 17
Study 15362516 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg TU (Group A)
Number of subjects: 30
Study 15362516 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg TU plus 150 mg DMPA (Group B)
Number of subjects: 30
Study 15362516 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg TU plus 300 mg DMPA (Group C)
Number of subjects: 30
Study 11323327 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 0
Study 11323327 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 0
Study 11323327 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (Remifentanil and Fentanyl)
Number of subjects: 0
Study 9152490 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized human albumin (NSA)
Number of subjects: 40
Study 9152490 — intervention group
Group type: COMPARATOR
Intervention: Heparinized saline (NS)
Number of subjects: 40
Study 9152490 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (NS and NSA)
Number of subjects: 40
Study 7954484 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (300 mg daily)
Number of subjects: 49
Study 7954484 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg daily)
Number of subjects: 49
Study 3502238 — intervention group
Group type: EXPERIMENTAL
Intervention: TFX and Levamisol
Number of subjects: 117
Study 3502238 — intervention group
Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom
Number of subjects: 117
Study 3502238 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex herb preparation PADMA
Number of subjects: 117
Study 3502238 — intervention group
Group type: COMPARATOR
Intervention: Climatotherapy in Czerniawa Sanatorium (Control)
Number of subjects: 117
Study 29777264 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg or 25 mg once daily
Number of subjects: 1175
Study 29777264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1175
Study 27354683 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN α Kinoid (IFN‐K)
Number of subjects: 6
Study 24004458 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimalist footwear (MFW)
Number of subjects: 10
Study 24004458 — intervention group
Group type: COMPARATOR
Intervention: Conventional running shoes (CRS)
Number of subjects: 10
Study 22541842 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed mirtazapine tablet formulation
Number of subjects: 0
Study 22541842 — intervention group
Group type: COMPARATOR
Intervention: Established branded mirtazapine tablet formulation
Number of subjects: 0
Study 20859551 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan + hydrochlorothiazide (Aml/Val+HCTZ)
Number of subjects: 344
Study 20859551 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine + hydrochlorothiazide (Aml+HCTZ)
Number of subjects: 344
Study 18665688 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief group cognitive-behavioral (CB) intervention
Number of subjects: 341
Study 18665688 — intervention group
Group type: COMPARATOR
Intervention: Supportive-expressive intervention
Number of subjects: 341
Study 18665688 — intervention group
Group type: COMPARATOR
Intervention: Bibliotherapy
Number of subjects: 341
Study 18665688 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 341
Study 17409842 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-carboplatin-paclitaxel combination chemotherapy (1000 mg/m gemcitabine on days 1 and 8, carboplatin AUC 5 on day 1, 175 mg/m paclitaxel on day 1 for three cycles)
Number of subjects: 44
Study 17409842 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-carboplatin-paclitaxel combination chemotherapy
Number of subjects: 44
Study 12854835 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent vertebral fractures
Number of subjects: 677
Study 12854835 — intervention group
Group type: COMPARATOR
Intervention: No prevalent vertebral fractures
Number of subjects: 677
Study 10795771 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 microg bolus intravenous, followed after 2 h by a continuous infusion of 25 microg/hr for 20 hr)
Number of subjects: 24
Study 10795771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8642191 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 0.5 mg, increased to 2 mg after 15 days
Number of subjects: 73
Study 8642191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg, increased to 20 mg after 15 days
Number of subjects: 73
Study 1557569 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian subset analysis
Number of subjects: 0
Study 3905203 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix 320
Number of subjects: 80
Study 3905203 — intervention group
Group type: COMPARATOR
Intervention: Niopam 300
Number of subjects: 80
Study 29933147 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care (IC) intervention consisting of nurse-led risk factor management, group-based counseling, individual problem-solving therapy, and antidepressant medications as needed.
Number of subjects: 4000
Study 29933147 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 4000
Study 29933147 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care (IC) intervention
Number of subjects: 4000
Study 26647376 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis
Number of subjects: 181
Study 26647376 — intervention group
Group type: COMPARATOR
Intervention: VUR alone
Number of subjects: 181
Study 26647376 — intervention group
Group type: COMPARATOR
Intervention: BBD alone
Number of subjects: 181
Study 26647376 — intervention group
Group type: COMPARATOR
Intervention: Neither BBD nor VUR
Number of subjects: 181
Study 26647376 — intervention group
Group type: EXPERIMENTAL
Intervention: BBD
Number of subjects: 181
Study 24866574 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month pretreatment with octreotide LAR
Number of subjects: 62
Study 24866574 — intervention group
Group type: COMPARATOR
Intervention: Direct surgery
Number of subjects: 62
Study 23078431 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (10 mg/day) for 8 weeks
Number of subjects: 185
Study 20557811 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPDGF (0.9 to 2.7 mg)
Number of subjects: 60
Study 18557665 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT)
Number of subjects: 31
Study 18557665 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (WLC)
Number of subjects: 31
Study 15863376 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (75 mg/m² cyclophosphamide orally on days 1-14, 60 mg/m² epirubicin and 500 mg/m² fluorouracil intravenously on days 1 and 8 for six cycles every 28 days for 6 months)
Number of subjects: 224
Study 15863376 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-intensive treatment (830 mg/m² cyclophosphamide and 120 mg/m² epirubicin intravenously on day 1, and 5 microg/kg filgrastim subcutaneously on days 2-13 for six cycles every 14 days for 3 months)
Number of subjects: 224
Study 15863376 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 224
Study 15863376 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-intensive treatment
Number of subjects: 224
Study 12027927 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 294
Study 12027927 — intervention group
Group type: COMPARATOR
Intervention: BHI 30
Number of subjects: 294
Study 10342414 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine patch
Number of subjects: 32
Study 10342414 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo) patch
Number of subjects: 32
Study 7732344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 100
Study 7732344 — intervention group
Group type: COMPARATOR
Intervention: Control group (other FD patients)
Number of subjects: 100
Study 2149674 — intervention group
Group type: EXPERIMENTAL
Intervention: 5, 10, 20, or 40 mg of fosinopril orally once daily for four weeks
Number of subjects: 418
Study 2149674 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo orally once daily for four weeks
Number of subjects: 418
Study 2149674 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide added during the final four weeks
Number of subjects: 418
Study 7025264 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-potassium di-citrato bismuthate (TDB) chewing tablets
Number of subjects: 60
Study 7025264 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine tablets
Number of subjects: 60
Study 31353997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen gel with 3% w/w levomenthol
Number of subjects: 182
Study 31353997 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac gel (1.16%)
Number of subjects: 182
Study 31353997 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen gel (5% w/w)
Number of subjects: 182
Study 28756902 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (15 mg/kg on day 1)
Number of subjects: 452
Study 28756902 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 452
Study 28756902 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab
Number of subjects: 452
Study 26547145 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls First Resilience Curriculum (RC)
Number of subjects: 2308
Study 26547145 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2308
Study 24015626 — intervention group
Group type: EXPERIMENTAL
Intervention: H-UPPP surgery with removal of partial pharyngeal muscle (Experimental group)
Number of subjects: 82
Study 24015626 — intervention group
Group type: COMPARATOR
Intervention: H-UPPP surgery without removal of partial pharyngeal muscle (Control group)
Number of subjects: 82
Study 24015626 — intervention group
Group type: COMPARATOR
Intervention: Comparison of L1, L2, L3 measurements between groups
Number of subjects: 82
Study 22027686 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet with 5 grams of fish oil daily (omega-6:omega-3 ratio of 2:1)
Number of subjects: 55
Study 22027686 — intervention group
Group type: COMPARATOR
Intervention: Control Western diet (omega-6:omega-3 ratio of 15:1)
Number of subjects: 55
Study 19378232 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid intravenous volume expansion (group A)
Number of subjects: 20
Study 19378232 — intervention group
Group type: COMPARATOR
Intervention: No expansion (group B)
Number of subjects: 20
Study 17530112 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 131
Study 17530112 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 131
Study 17530112 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 131
Study 17530112 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch and bupropion
Number of subjects: 131
Study 15387158 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained outpatient commitment
Number of subjects: 0
Study 15387158 — intervention group
Group type: COMPARATOR
Intervention: Brief outpatient commitment or none
Number of subjects: 0
Study 15387158 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved treatment adherence
Number of subjects: 0
Study 11488180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 40
Study 11488180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11148914 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with alcohol dependence syndrome (21 patients)
Number of subjects: 21
Study 11148914 — intervention group
Group type: COMPARATOR
Intervention: Control group of healthy persons (24 persons)
Number of subjects: 21
Study 9247986 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mg melatonin
Number of subjects: 1
Study 9247986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 1520054 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine sulfate (200 mg at supper and 300 mg at bedtime)
Number of subjects: 27
Study 1520054 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (800 U at bedtime)
Number of subjects: 27
Study 1520054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 6241767 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms HBV vaccine
Number of subjects: 100
Study 6241767 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms HBV vaccine
Number of subjects: 100
Study 6241767 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micrograms HBV vaccine
Number of subjects: 100
Study 6241767 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 100
Study 31028216 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed valve
Number of subjects: 552
Study 31028216 — intervention group
Group type: COMPARATOR
Intervention: Baerveldt implant
Number of subjects: 552
Study 29526236 — intervention group
Group type: EXPERIMENTAL
Intervention: Amla (Phyllanthus emblica L.) 500 mg tablets, two tablets twice a day for 4 weeks
Number of subjects: 68
Study 29526236 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets similar to Amla prescription
Number of subjects: 68
Study 26922847 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional TENS therapy for 20 minutes
Number of subjects: 30
Study 26922847 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS therapy
Number of subjects: 30
Study 25034632 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism glasses
Number of subjects: 105
Study 25034632 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual search training
Number of subjects: 105
Study 25034632 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 105
Study 23107591 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvirin inactivated vaccine
Number of subjects: 100
Study 23107591 — intervention group
Group type: EXPERIMENTAL
Intervention: Afluria inactivated vaccine
Number of subjects: 100
Study 23107591 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluarix inactivated vaccine
Number of subjects: 100
Study 23107591 — intervention group
Group type: COMPARATOR
Intervention: Live influenza vaccine (Flumist)
Number of subjects: 100
Study 23107591 — intervention group
Group type: COMPARATOR
Intervention: Inactivated vaccines (general)
Number of subjects: 100
Study 23107591 — intervention group
Group type: COMPARATOR
Intervention: Live vaccine
Number of subjects: 100
Study 20552817 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex Decongestive Therapy (CDT) alone
Number of subjects: 112
Study 20552817 — intervention group
Group type: COMPARATOR
Intervention: Modified CDT (MCDT) combined with Intermittent Pneumatic Compression (IPC)
Number of subjects: 112
Study 18568788 — intervention group
Group type: COMPARATOR
Intervention: Estrogen-progestin treatment (EPT) in premenopausal women
Number of subjects: 35
Study 18568788 — intervention group
Group type: COMPARATOR
Intervention: Estrogen-progestin treatment (EPT) in postmenopausal women
Number of subjects: 35
Study 16075681 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyramin bioregulator
Number of subjects: 0
Study 12095178 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (14-day course)
Number of subjects: 13
Study 12095178 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast
Number of subjects: 13
Study 10636373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 0
Study 8565024 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg twice daily
Number of subjects: 270
Study 8565024 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone 1500 mg once daily
Number of subjects: 270
Study 8565024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 2035374 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg daily if serum cholesterol < 300 mg/dl; 40 mg daily if serum cholesterol ≥ 300 mg/dl)
Number of subjects: 157
Study 2035374 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone (control group)
Number of subjects: 157
Study 30670666 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow indicator covered
Number of subjects: 42
Study 30670666 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow indicator covered after standard exposure (Group B)
Number of subjects: 42
Study 30670666 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow indicator covered before standard exposure (Group A)
Number of subjects: 42
Study 30670666 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups A and B
Number of subjects: 42
Study 28544580 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC) for 1 year
Number of subjects: 0
Study 28544580 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) for 2 years
Number of subjects: 0
Study 28544580 — intervention group
Group type: COMPARATOR
Intervention: Pooled cohort (MMF + CYC)
Number of subjects: 0
Study 28544580 — intervention group
Group type: COMPARATOR
Intervention: CYC in SLS I
Number of subjects: 0
Study 28544580 — intervention group
Group type: COMPARATOR
Intervention: Placebo in SLS I
Number of subjects: 0
Study 27041740 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-guided conversations focusing on children's feelings
Number of subjects: 43
Study 27041740 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-guided conversations focusing on the content of the video
Number of subjects: 43
Study 27041740 — intervention group
Group type: EXPERIMENTAL
Intervention: Less stress (self‐reported happiness and observed negative affect) before and after the stressor
Number of subjects: 43